SELLAS Life Sciences Group, Inc.
NASDAQ:SLSBiotechnology
+$0.31 today
- Market cap
- $3.66B
- Beta
- 2.53
- P/E (TTM)
- -47.3
- EPS (TTM)
- -$0.17
Volume 35.53M
Average 7.79M
SLS EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
SELLAS Life Sciences Group, Inc.NASDAQ: SLS
EBITDA · Q3 FY2026 · quarter ended Sep 2026
EBITDA turns negative
Q3 FY2026 EBITDA was -$10.09M, compared with $292K a year earlier. Trailing-twelve-month EBITDA was -$35.76M.
Context
- EBITDA increased in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 1 analysts of $281.57K (+101.0%) for the fiscal year ending Dec 2026, a step up from the -4350.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$10.09M-5.1% QoQ
- Last fiscal yearDec 2025
- -$26.86M-4350.5% YoY
- LTMSep 2026
- -$35.76M-89.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -3555.8% | +56.0% | +3611.8 pp |
| 1 year | -4350.5% | +101.0% | +4451.5 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (26.86M) USD
- Year-over-year change
- -4350.5%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (26.86M) | -4350.5% |
| FY2024 | 2024-12-31 | 632K | +19.5% |
| FY2023 | 2023-12-31 | 529K | +101.7% |
| FY2022 | 2022-12-31 | (31.49M) | -71.9% |
| FY2021 | 2021-12-31 | (18.32M) | — |
EBITDA vs competitors
How SLS compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -89.6% is the 9th highest of 11, against a peer median of -5.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $2.07B USD | +52.6% | +43.2% | 35.5% | |
| LTM Aug 2026 | $322.61M USD | +243.1% | — | 46.0% | |
| LTM Sep 2026 | -$35.76M USD | -89.6% | — | — | |
| LTM Mar 2026 | -$50.64M USD | -7.0% | — | 32.2% | |
| LTM Mar 2026 | -$76.13M USD | +39.6% | — | 455.3% | |
| LTM Mar 2026 | -$100.38M USD | -3.7% | — | 287.9% | |
| LTM Mar 2026 | -$135.46M USD | +55.2% | — | 60.1% | |
| LTM Mar 2026 | -$145.24M USD | -14.0% | — | — | |
| LTM Mar 2026 | -$158.86M USD | -1227.0% | — | 1336.8% | |
| LTM Sep 2026 | -$284.54M USD | -45.7% | — | — | |
AAPGAscentage Pharma Group International | FY2025 | -CN¥1.1B CNY | -360.8% | — | 196.1% |
| Peer median (excluding SLS) | — | -5.3% | +43.2% | 128.1% | |
Competitors are the stored peer set for SLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 7.6M | 1M | 0 | 0 | 0 |
| Cost of Revenue | 200K | 100K | 0 | 0 | 0 |
| Gross Profit | 7.4M | 900K | 0 | 0 | 0 |
| Gross Margin | 97.4% | 90.0% | — | — | — |
| Research & Development | 21.37M | 30.27M | 24.01M | 19.1M | 16.02M |
| Selling, General & Admin | 11.32M | 12.58M | 13.86M | 12.42M | 12.25M |
| Operating Expenses | 32.69M | 42.85M | 37.87M | 31.51M | 28.27M |
| Depreciation & Amortization | 1.27M | 457K | 37.87M | 31.51M | 0 |
| EBITDA | (18.32M) | (31.49M) | 529K | 632K | (26.86M) |
| EBITDA Margin | -241.1% | -3149.3% | — | — | — |
| Operating Income | (25.29M) | (41.95M) | (37.87M) | (31.51M) | (28.27M) |
| Operating Margin | -332.8% | -4195.0% | — | — | — |
| Interest Income | 6K | 317K | 525K | 632K | 1.41M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 4.36M | 649K | 529K | 632K | 1.41M |
| Income Before Tax | (20.94M) | (41.3M) | (37.34M) | (30.88M) | (26.86M) |
| Pre-Tax Margin | -275.5% | -4130.1% | — | — | — |
| Income Tax Expense | (237K) | 0 | 0 | 0 | 0 |
| Net Income | (20.7M) | (41.3M) | (37.34M) | (30.88M) | (26.86M) |
| Net Margin | -272.4% | -4130.1% | — | — | — |
| EPS (Basic) | (1.34) | (2.13) | (1.34) | (0.50) | (0.25) |
| EPS (Diluted) | (1.34) | (2.13) | (1.34) | (0.50) | (0.25) |
| Weighted Avg Shares | 15.48M | 19.4M | 27.78M | 61.2M | 109.05M |
| Weighted Avg Shares (Diluted) | 15.48M | 19.4M | 27.78M | 61.2M | 109.05M |
SELLAS Life Sciences Group, Inc.
NASDAQ:SLS
Intrinsic Alpha fair value
Locked
Current Price
$17.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.